press release: Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S.

Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S.

EDMONTON, Jan. 22, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has achieved 50% accrual having enrolled the 40^th patient in its ongoing 80 patient Phase II Oregovomab front-line chemo-immunotherapy clinical trial in Italy and the U.S.

The objective of this study is to confirm that optimally dosed oregovomab in combination with standard front-line chemotherapy for advanced ovarian cancer will generate an improved immune and clinical response, as seen in preliminary phase II studies, and permit the best design of a definitive phase III program to follow. Currently, there are 8 clinical trial centers in Italy enrolling patients, with Professor Roberto Angioli at Policlinico Universitario Campus Bio-Medico Di Roma acting as the study chair. The Company is adding three additional centers in the U.S., to the two active U.S. sites, through the COGI (Cooperative Ovarian Cancer Group for Immunotherapy) clinical trials group, under the leadership of Professor Jonathan Berek at the Stanford Women's Cancer Center, Stanford Cancer Institute.

"We are excited to reach the mid-point in patient enrollment for this pivotal 80 patient clinical trial", said Madi R. Madiyalakan, Ph.D., Chief Executive Officer for Quest. "With 13 centers currently participating in the trial, we are hopeful that we will achieve full patient enrollment within this year.  This program not only is evaluating the latest concepts of combination chemo-immunotherapy for ovarian cancer, but is also providing critical data to facilitate the pending clinical development of additional cancer antibody immunotherapeutics within our technology pipeline."